Le Lézard
Classified in: Health
Subject: MAT

Curio Wellness Granted The Country's First US Patent for A Cannabis Sleep Product


Market leader is granted a U.S. Patent for its cannabis product Good Nighttm Sleep Aid Product

TIMONIUM, Md., June 20, 2023 /PRNewswire-PRWeb/ -- Curio Wellness, a cGMP-certified, vertically integrated cannabis company and market-leading innovator of health and wellness products derived from cannabis, was awarded a Utility patent for Good Nighttm by Curio, marking a significant milestone for the company and brand.

Good Nighttm, Maryland's only pulse-release cannabis sleep aid line has led the market since its release in 2021. The ratio tablet is designed to help consumers fall asleep faster, stay asleep longer and reduce morning grogginess.

Curio Wellness was granted US Patent (11,654,130) on May 23, 2023 which will be in force until January 2042. Good Night's patented technology secures a unique, pulse-delivery system for medicinal cannabis sleep products, demonstrating Curio's adherence to driving innovation, breaking boundaries and improving patient outcomes and the overall experience for cannabis-derived medicine.

"This patent validates the revolutionary nature of the product development efforts at Curio and the novel application of our pulse-release technology," added Dr. Edward Rudnic, Chairman of Curio's Scientific Board and its Chief Scientific Officer. "This is the first of many condition-specific product patents we anticipate to issue over the coming years thanks to the continued innovation and unmatched clinical testing executed by Curio's product innovation team."

The proprietary pulse-release doses in two stages for sustained release and has been scientifically proven to improve sleep quality. An independent study, published in the American Journal of Endocannabinoid Medicine, found that participants woke up less frequently and spent less time awake at night. Additionally, 65 percent of participants reported feeling more satisfied with their sleep and feeling better rested during the day four times per week, double the rate found before the trial.

"Curio's medical-based research methods are the foundation of all the innovative work we have accomplished thus far," said Michael Bronfein, CEO of Curio Wellness and co-inventor. "This patent is a significant and exciting milestone for Curio, and solidifies our commitment to developing cutting-edge cannabis products that enable our patients to enjoy a better quality of life."

Curio Wellness is the leading developer of cannabis-derived medical products in Maryland. In addition to cannabis sleep aids, in 2022 Curio launched GI by Curiotm targeting gastrointestinal health issues as well as Move by Curiotm targeting muscle and joint pain. Earlier this year, it launched Good Daytm targeting anti-anxiety and stress relief. Curio Wellness is Maryland's first cGMP-certified manufacturer, which means that its products meet the same quality and safety standards required by the FDA and those produced by the world's leading pharmaceutical companies.

About Curio Wellness
Founded in 2014 in Baltimore, Maryland, Curio Wellness is a cGMP-certified, vertically integrated cannabis company and trusted healthcare partner. Recognized as the leading wellness brand in cannabis by BDS Analytics, Curio is committed to serving patients with safe, effective, and reliable cannabis-based medicine. For more information, visit https://curiowellness.com.

Media Contact

Katie Beecher, Abel Communications, 410-989-8585, kbeecher@abelcommunications.com

 

SOURCE Curio Wellness


These press releases may also interest you

at 02:00
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...

at 01:54
FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...

16 mai 2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...

16 mai 2024
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...



News published on and distributed by: